Concepts in the Treatment of Bladder Cancer - Clinical and Experimental by SOLOWAY, Mark S.
Title Concepts in the Treatment of Bladder Cancer - Clinical andExperimental
Author(s)SOLOWAY, Mark S.










Urol. Jap. Vol. 28 12, December 1982'
CONCEPTS 
 CANCER
IN THE TREATMENT OF  BLADDER 
-CLINICAL AND EXPERIMENTAL
                Mark 
Professor, Department of Urology,
S. SOLOWAY, M. D. 
University of Tennessee Center .forthe Health Sciences
   Assessment of optimal management of a patient with bladder cancer will be dependent on tumor 
grade, stage and multiplicity as well as the patient's medical status. Thus the urologist should attempt 
to assess the extent of urothelial abnormality and obtain as accurate a stage as possible. Despite 
endoscopy, biopsy, and bimanual examination under anesthesia, the precise depth of invasion is often 
inaccurate when dealing with a tumor which has invaded into the muscle. Newer techniques such 
as endoscopic ultrasound and CAT scan may allow the clinician to improve his accuracy in gauging 
the stage of invasive tumors. Selected site cold cup biopsies are advantageous in determining the 
extent of urothelial abnormalities, e.g. dysplasia, carcinoma in situ (CIS). Prognosis is largely de-
pendent on the depth of tumor invasion, with the likelihood of dissemination much greater once the 
tumor has invaded into the muscular wall of the bladder. Thus those patients with stage Ta, Tl or 
Tis are managed endoscopically with supplemental intravesical chemotherapy and those with T2 
or greater lesions are treated with radiation and/or extirpative surgery. 
Key words: Bladder cancer, Clinical, Experimental, Treatment
  SUPERFICIAL BLADDER CANCER 
Endoscopy
  The urologist can gain a great deal of 
information at the time of the initial 
endoscopic evaluation. It is critical to 
closely evaluate all portions of the bladder 
and often this will require complete bladder 
relaxation utilizing either a general or 
regional anesthesia. A bladder diagram 
should be available so the endoscopist can 
make a permanent record of the number
and size of each identifiable urothelial 
abnormality and the site of the biopsies. 
At this initial evaluation the selected site 
biopsies can be quite helpful in determining 
the extent of urothelial abnormalities. 
Usually these selected site biopsies are 
obtained lateral to each ureteral orifice, 
the posterior midline, and the dome. A 
biopsy from the prostatic urethra might be 
warranted in men with multifocal disease, 
tumor located near the bladder neck, or 
carcinoma in situ.
  Any visible tumor should be resected as 
completely as possible with the surrounding 
urothelium fulgurated. The completeness
of resection obviously depends upon the
extent of disease. 
Pathology
  The majority of urothelial tumors appears 
as exophytic neoplasms in which the cells 
are arranged on fibrovascular stalks. These 
papillary tumors are usually of low cytologic 
grade; however they have a marked pro-
pensity for "recurrence". There may be a 
mixture of cytologic grades (I—III) within 
each neoplasm.
  Tumors which are flat or sessile are 
thought to develop from urothelial atypia 
or dysplasia without concomitant hyper-
plasia. Because there is no fibrovascular 
stalk; it may be difficult to identify these 
l sions endoscopically. There is a paucity 
of information on the natural history of 
these flat lesions. The terms "dysplasia" 
or "atypia" correspond by nature of their 
cellular architecture to grade I or grade II 
papillary tumors. Therefore it might be 
logical to term these lesions flat, transitional 
cell carcinoma grade I and II. It is 
probably preferable, however, to retain the 
term "dysplasia" until the exact relationship
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of these lesions to carcinoma is better 
understood. On the other hand, flat 
tumors of high cytologic grade (III) are 
termed appropriately "carcinoma in situ".
  Carcinoma in situ is often multifocal and 
the cells lack an orderly progression from 
the basal layer to the surface. Nuclear 
pleomorphism is prominent. Mitoses may 
be frequent. Carcinoma in situ is not 
always endoscopically apparent and selected 
site or random mucosal biopsies of endo-
scopically normal-appearing urothelium will 
frequently identify CIS. It should be 
emphasized that the natural history of 
carcinoma in situ is quite variable. 
 Cytology
  Cytologic evaluation of urine obtained 
by voiding, via the cystoscope, or by 
bladder washing has become an integral 
part of the total evaluation of patients with 
urothelial carcinoma. Since the accuracy 
of urinary cytology is high with lesions of 
higher cytologic grade, it is particularly 
helpful in the detection of carcinoma in situ. 
A positive cytology in a patient with a 
grade I tumor might alert the urologist to 
be suspicious of a higher grade neoplasm 
since grade I tumors differ only slightly in 
their cytologic features from those of normal 
urothelial cells and thus they are not usually 
identifiable on examination of the urine. 
With increasing reliance on cytology as a 
sampling of the urothelium, the frequency 
of endoscopy might be reduced in patients 
being monitored following resection of a 
superficial tumor if the cytopathologist is 
experienced and the cytology is negative.
  Although intravesical chemotherapy can 
produce some cytologic alterations in ex-
foliated urothelial cells, the experienced 
cytopathologist can usually distinguish 
these effects from malignant cells. It is 
critical, however, that the clinician provide 
the cytopathologist with pertinent data 
related to the patient's prior therapy, e.g. 
intravesical chemotherapy, systemic chemo-
therapy, radiation. 
New Occurrences vs. True Recurrences
  The five-year survival for patients with 
superficial bladder cancer is excellent,
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ranging from 63-82 per cent. The chance, 
however, of a subsequent tumor is quite 
high, ranging from 50-70 per cent1^'4>. 
There are probably two separate etiologies 
for this high incidence of subsequent tumors. 
Histologic mapping of the bladder following 
cystectomy for invasive bladder cancer has 
demonstrated multifocal carcinoma or 
carcinoma in situ in approximately 80 per 
cent of specimens5-7). Further evidence for 
multifocal neoplasia comes from studies in 
which mucosal biopsies have been obtained 
from normal-appearing mucosa at sites 
distant from an obvious tumor. The 
incidence of urothelial dysplasia, CIS, or 
cancer in these specimens ranges from 20-80 
per cent8-10 .
 The second possible explanation for the 
high incidence of subsequent tumors follow-
ing endoscopic resection/fulguration may be 
t e implantation of tumor cells following 
the operative procedure. These should be
termed true recurrences. Trauma to the 
urothelium during the endoscopic procedure 
may provide a fertile site for viable tumor 
cells to implant and grow.
  Although implantation has been con-
jectured as a possible reason for the high 
i cidence of subsequent tumors, there has 
been little experimental data until recently 
to confirm this hypothesis. MacDonald 
and Thorson" successfully transplanted
transitional cell tumors to mucosal-lined 
pouches previously created in recipient 
dogs. Weldon and Soloway12) showed a 60 
per cent incidence of transitional cell tumor 
implantation in mice following pre-treat-
ment of the bladder with n-methyl-n-
nitrosourea (MNU). There was only a 13 
per cent incidence of implantation in 
bladders without prior alteration. MNU 
produces a diffuse cystitis and epithelial 
denudation presumably allowing sites for 
tumor implantation. MNU treatment, 
however, may not simulate the clinical 
situation. Thus a technique was devised 
to reproducibly cauterize a small portion
of the murine urothelium13). These two 
methods were recently compared.
 The animals used were female C3H/He 
mice. The tumor, MBT-683, is a poorly 
differentiated transitional cell carcinoma
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which originated as an invasive neoplasm 
in a female C3H/He mouse which had 
ingested the carcinogen FANFT for eleven 
months. The tumor has been serially 
transplanted in syngeneic mice and was 
utilized in its thirtieth transplant generation. 
A single cell suspension of this tumor was 
prepared by trypsin enzymatic dissociation 
as previously described14).
  Fifty-seven C3H/He mice were randomly 
divided into three groups. Group I (16 
mice) served as controls and received the 
tumor cell suspension intravesically. Group 
II (25 mice) had urothelial injury produced 
by intravesical MNU prior to instillation of 
the tumor cell suspension. Group III (16 
mice) had urothelial damage produced by 
cauterization prior to insertion of tumor
cells.
  The mice receiving the MNU received a 
fresh solution of 7.5 mg/cc. A totalof 
0.1 cc was injected intravesically. This was 
performed two days prior to instillation of 
the tumor cells. The drug was placed
into the bladder via a small urethral. 
polyethylene catheter.
  Mice in Group III had the posterior 
portion of the bladder cauterized by a 
transurethrally placed insulated electrode 
which was attached to a Bovie electrocautery 
unit. Perforation of the bladder occurred 
in three animals and an additional mouse 
died four days following cauterization pre-
sumably of infection. Thus 12 mice were 
analyzed for tumor development.
 All mice received 2.09 x 106 viable MBT-
683 transitional tumor cells in a volume of 
0.1 cc. The cells were instilled transure-
thrally. Mice were observed for 28 days. 
Bladders were removed and evaluated for 
the presence of tumor.
 Tumors developed in one of 16 (6%) 
mice in the control group (Group I) (Table 
Table 1. Comparison of MNU and cauterization
on the incidence of tumor cell inplan-
tation
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1). The incidence of tumor was 28 per 
cent (7 of 25) in the mice pre-treated with 
MNU two days prior to the intravesical
instillation of tumor cells. This difference 
as not statistically significant, p <0.1.
 Mice in Group III which had the 
posterior portion of the bladder fulgurated 
immediately prior to instillation of tumor 
cells exhibited 67 per cent incidence of 
bladder tumors. This difference is highly 
significant, p <0.005, and confirms that 
transitional tumor cells will preferentially 
implant on the altered urothelial surface.
  There is increasing evidence which sug-
gests that some of the subsequent tumors 
seen following endoscopic resection in man 
may be true recurrences resulting from 
implantation. Urologists have often com-
mented on the frequency of subsequent 
tumors at the vesical neck, in the prostatic 
urethra, or in the bladder dome and have 
implicated trauma from the initial resec-
tion15,16> This circumstantial evidence as
well as the different sites of "recurrent" 
tumors when compared to initial tumors was
the subject of a recent review artie1e17'. 
Intravesical Chemotherapy
 Since both multifocal new tumor occur-
rence and implantation appear to contribute 
to the high incidence of subsequent tumors, 
it seems futile to rely solely on transurethral 
resection for the long-term management of 
patients with superficial bladder cancer. 
This is particularly true for those that have 
demonstrated a likelihood for frequent 
recurrences. Topical chemotherapy initiated 
shortly after surgical resection might reduce 
the likelihood of true recurrences by 
eradicating viable tumor cells remaining
in contact with the urothelium after 
endoscopic surgery and might also diminish 
th number or frequency of new occurrences 
by exerting a cytoxic action on the micro-
scopic foci of carcinoma or CIS. Intravesical 
instillation of chemotherapeutic agents 
places a relatively high concentration of
drug in contact with the urothelium while 
minimizing systemic toxicity. The agent 
most frequently utilized for intravesical
chemotherapy is thio-tepa. This agent has 
been carefully evaluated both as definitive
1542
Table
         Acta Urol. Jap. Vol. 28, No. 12, 




VEENEMA  ET .AL  .18 
ABBASSIAN AND WALLACE19 




















therapy of existing superficial tumors as well 
as for prophylaxis following complete endo-
scopic resection/fulguration.
  The reported response rate, including 
both complete and partial responses when 
utilized for definitive therapy of patients 
with multiple papillary tumors, ranges 
from 47-82 per cent18-21) (Table 2). The 
dose usually employed consists of four 
weekly instillations of 30-60 mg diluted in 
an equal volume of sterile water followed 
by a monthly dose. The major side effect 
of this drug is myelosuppression.
  There is a lack of long-term follow-up on 
patients receiving thio-tepa for definitive 
therapy of superficial bladder cancer. Thus 
although there is a high likelihood that the 
drug is of initial benefit, the subsequent 
incidence of tumors while receiving main-
tenance thio-tepa has not been determined.
  In an effort to better define the histologic 
and cytologic alterations resulting from 
repeated thio-tepa instillations, we have 
carried out a series of experiments utilizing 
an animal model to avoid the uncontrolled 
variability inherent in human studies and 
permit the examination of the entire 
bladder following thio-tepa instillation for 
comparison with histologic and cytologic 
findings. The initial investigation22) analyz-
ed the effect of a single dose of thio-tepa 
(compared to saline) on the normal murine 
urothelium. No consistent morphologic
differences were encountered between the 
two solutions. In particular there were no 
atypical cells such as described in association 
with irradiation or cyclophosphamide.
  A subsequent series of studies23-24) evaluat-
ed the effect of thio-tepa on the induction 
of urothelial tumors by the carcinogen 
FANFT. Thio-tepa or saline was initiated 
when the animals were known to have
either atypia or carcinoma in situ. Following 
three weeks of therapy, prominent cellular 
degeneration and vacuolization were ob-
served both by urine cytology and histology 
and are believed to represent toxic effects 
of therapy. These effects were not limited 
to the drug-treated group but were also 
se n in animals receiving saline. They 
we e, however, more prominent in those 
treated with the alkylating agent. Nuclear 
changes which might reflect alterations of 
c llular metabolism were uncommon. The 
incidence of tumors did not significantly 
differ between the treated and control 
animals. There were, however, significant-
ly fewer high stage tumors in the thio-tepa 
tr ated group compared to the controls. 
This suggests that thio-tepa retarded the 
progression of neoplasms from low grade, 
non-invasive lesions to high grade, invasive 
lesions.
  If these animal studies reflect what 
occurs in the human, thio-tepa may cause 
de udation of papillary growth with result-
ant flattening of fibrovascular stalks 
re ering them endoscopically invisible. 
Thus the effect of therapy as denoted by 
endoscopy, will be recorded as a complete 
response although abnormal basal cells may 
not be eradicated. Thus given sufficient 
time, the tumor would reappear. This, of 
course, does not negate the beneficial effects 
of thio-tepa since such a denuding action 
might spare the patient repeated endoscopic 
sessions for fulguration of low grade tumors. 
I  addition, the toxic effect of the drug 
may prevent implantation of tumor cells 
when instilled following a transurethral 
resection.
  A number of studies21,2s-27) have now 
compared the efficacy of thio-tepa pro-
phylaxis compared to a non-treated group.
Table
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3. Incidence of recurrence following thio-tepa prophylaxis
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(Table 3) The dosage, administration 
schedule, and, in particular, the delay in 
the initiation of the drug following resection 
of tumors vary widely in the studies. 
Burnand et a1.25 found minimal side effects 
following instillation of a single 90 mg dose 
immediately post-resection. The drug re-
mained in the bladder for only 30 minutes. 
England et al.28) utilized thio-tepa in 40 
patients as prophylaxis following endoscopic 
resection of multiple tumors. Twenty-seven 
of the patients had grade I and 13 had 
grade II lesions. All of the patients with 
grade II tumors had invasion into the 
lamina propria. The 30 mg dose was 
instilled on days 1, 3, and 5 post-surgery. 
The authors considered patients as respond-
ing if there was no recurrence or if the 
incidence of subsequent tumors was reduced 
to a small fraction of the established previous 
pattern. Thirty-one (78 per cent) of the 
treated patients responded. There was no 
difference in the response rate between 
patients with grade I or grade II tumors. 
Of 13 patients with grade II, stage T1 
lesions, only two failed to respond. Twenty-
six per cent of the responders have remained 
tumor-free without thio-tepa maintenance. 
Three of the entire group of patients died 
of bladder cancer during the follow-up. 
The responders could usually be denoted 
after the first course of intravesical therapy. 
Usually there was a reduction in the 
number of subsequent tumors with eventual 
clearance confirmed by selected site mucosal 
biopsies.
  There have been two recent multi-insti-
tutional collaborative group studies evaluat-
ing the prophylactic effect of thio-tepa 
following endoscopic resection/fulguration 
of superficial bladder cancer. The National 
Bladder Cancer Clinical Collaborative
Group21) compared prophylactic thio-tepa 
utilizing either 30 or 60 mg compared to 
a group not receiving chemotherapy. 
Therapy was initiated one month following 
r section. The disease-free incidence at 
ne year was 66 per cent for those who 
received thio-tepa compared to 40 per cent 
in the control group. This was a statistically 
significant difference, p<0.02. There was 
no difference between the two dosages.
  The EORTC Genito-Urinary Tract 
C ncer Cooperative Group27) also compared 
the disease-free interval following prophy-
lactic intravesical chemotherapy of super-
ficial bladder tumors. The drugs compared 
were thio-tepa, 30 mg/30 cc, VM-26, 50 
mg/30 cc, or no therapy. Initiation of 
rapy was delayed for four weeks following 
surgery and was continued monthly for 
eleven months. The recurrence rate was 
49.3 per cent in the thio-tepa group, 62.0 
per cent in the VM-26 group, and 52.2 
per cent in the control group. There was 
no significant difference among the treat-
ment regimens. There was a difference, 
however, in the number of tumors per 100 
patient months of follow-up. Statistical 
analysis revealed a lower recurrence rate 
for those patients receiving thio-tepa com-
pared to those receiving VM-26 or the
control.
  Since I am concerned that implantation 
might be a factor in the recurrence rate, 
it is my preference to initiate intravesical 
hemotherapy as soon as feasible following 
transurethral resection or fulguration. If 
the patient is less than 70 years old and 
the resection is not extensive, I utilize 60 
mg diluted in 60 cc of sterile water for an 
instillation time of two hours and initiate 
this the day following resection. Patients 
older than 70 years receive 30-45 mg. If
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there has been an extensive resection, the 
instillation may be delayed for three to 
five days. If there is not significant 
myelosuppression, therapy is continued 
weekly for four weeks and then monthly.
During the last couple of years there has
been an acceleration in the number of 
drugs introduced for intravesical chemo-
therapy. Mitomycin C (MMC) was first 
reported to be efficacious for intravesical 
chemotherapy in 1975. Mishina29) treated 
50 patients at a dose of 20 mg/20 ml
sterile water three times a week. He 
reported a 44 per cent complete response 
and 32 per cent partial response rate. 
Patients with low grade lesions had an 89 
per cent response rate compared to 36 per 
cent for those with high grade tumors. 
Bracken et al.30) reported the effectiveness 
of intravesical MMC in 43 patients with 
Tis or Ti transitional cell carcinoma. This 
was used as definitive therapy for patients
not amenable to transurethral resection. 
The dose ranged from 20 to 60 mg and 
was given in eight consecutive weekly 
doses. The overall response rate was 84 
per cent (49 per cent complete, 30 per cent 
partial and 5 per cent improved) . It was 
felt that the optimal dose was 40 mg.
  At the University of Tennessee Center 
for the Health Sciences I have treated 35 
patients with superficial bladder cancer 
with MMC. This is now twice the number 
of our original report31). Eight weekly doses 
of 30 mg in 30 cc sterile water were 
administered to six patients and 29 received 
40 mg/40 cc. Seventy per cent of the 
patients failed thio-tepa. The ages of the 
23 men and 12 women ranged from 49 to 
97 years (mean 71 years). At least one 
tumor was histologically confirmed in each 
patient. If the patient had a solitary 
lesion, this was not completely excised at 
the time of biopsy. All patients had one
or more urothelial tumors at initiation of 
mitomycin C therapy. Six patients had 
multifocal carcinoma in situ. Twelve patients 
had grade III tumors (CIS=grade III).
  The criteria for complete response of an 
exophytic tumor included the disappearance 
of endoscopically visible lesions and a 
negative urinary cytology. If a patient had 
only CIS, complete response was based on 
random cold cup biopsy-proven absence of 
tumor and a negative cytology. A partial 
response required more than a 50 per cent 
reduction in the size of all tumors and the 
absence of new neoplasms. The majority 
of complete and some of the partial res-
ponders received monthly mitomycin C.
  The overall response rate was 83 per cent. 
(Table 4) No tumor was evident in 16 
(46 per cent); 13 patients (37 per cent) 
achieved a partial response. Some of the 
partial responders only had a positive 
cytology. The response rate appeared to 
be somewhat better for those receiving a 
dose of 40 mg. Interestingly, higher grade 
tumors responded slightly better than low 
grade lesions (Table 5). At the twelve 
week endoscopic session, complete necrosis 
of previous papillary tumors was frequently 
observed. Biopsy specimens usually cannot 


















 Although systemic mitomycin C is myelo-
suppressive, intravesical treatment did not 
result in leukocyte or platelet count reduc-
tion. This is consistent with the lack of 
absorption as indicated by serum samples 
btained at various periods of time after
 Soloway  : Treatment 
MMC instillation. This lack of absorption 
may be related to the higher molecular 
weight compared to that of thio-tepa (334 
vs 189).
 The primary side effect related to 
mitomycin C was moderate cystitis in four 
patients and drug-related desquamation of 
the palmar skin in four. In two patients 
this palmar reaction was mild and subsided 
after hydrocortisone cream. In the other 
two, the rash was severe and accompanied 
by a macular rash in the perineal region 
with penile edema. We have performed 
a series of patch and scratch tests on these 
patients with concurrent • controls and
believe that most of the cutaneous reactions 
are due to a contact dermatitis. Careful 
cleaning of the hands and perineum 
following the initial instillation of MMC 
and all subsequent voidings for the first 24 
hours can prevent many of these reactions.
  In a similar manner to the studies 
performed in our laboratory on thio-tepa, 
we have analyzed the drug-induced uro-
thelial alterations as a result of MMC32). 
Once again this involved placing mitomycin 
C into murine bladders and subsequently 
studying the urinary cytology and histology 
following cystectomy and multiple step 
sectioning of the bladders. Cellular ab-
normalities occurring after mitomycin C 
were not drug specific and were readily 
distinguishable from neoplastic changes. 
Thus it is felt that the drug will not limit 
the efficacy of urinary cytology in the 
follow-up of patients treated with MMC.
 Mitomycin C may be the most active of 
the drugs currently under investigation for 
intravesical chemotherapy. The low in-
cidence of side effects is a major advantage. 
A prospective trial comparing MMC with 
thio-tepa for definitive therapy of measur-
able superficial tumors is currently under-
way by the National Bladder Cancer 
Collaborative Group.
  Since the carcinogen-induced animal 
model for bladder cancer has been helpful 
in selecting drugs for systemic chemotherapy 
we compared the effectiveness of several 
intravesically administered drugs on sub-
sequent tumor incidence and tumor size. 
To mimic the clinical situation, the
of bladder cancer1545
carcinogen FANFT was not discontinued 
during the experiment. Human urinary 
bladder tumors may be caused by chemical 
carcinogens and these may persist.
 One hundred and six C3H/He female 
mice were randomly divided into a control 
group (31 mice) and three treatment 
groups of 25 each. After 38 weeks on 
FANFT, intravesical chemotherapy was 
initiated and consisted of cis-diamminedi-
chloroplatinum II (DDP), 18 mg/kg; mito-
mycin C, 10 mg/kg; or thio-tepa, 5 mg/kg. 
These doses represent the highest non-toxic 
dose utilized by intravesical instillation. 
Therapy was continued weekly for three 
weeks; the fourth dose was delayed one 
week to allow sufficient recovery following 
the earlier instillations. All of the drugs 
remained in the bladder for a minimum of 
30 minutes which was usually the duration 
of the intraperitoneal administered anes-
thesia. All animals were sacrificed during 
week 46 and the bladders processed for 
routine light microscopy for identification 
of the presence of tumor and tumor stage.
 The incidence of tumors in the control 
group was 96 per cent. (Table 6) The 
tumor incidence in the groups treated with 
thio-tepa, mitomycin C, and DDP were 71 
per cent, 71 per cent and 40 per cent 
respectively. This reduction was significant 
in the groups receiving mitomycin C and 
DDP. The highest percentage of normal 
bladders was in animals receiving DDP, 
60 per cent vs 4 per cent controls, p <0.001.
Table 6. Comparison of intravesical chemothe-
         rapeutic agents on the incidence of 




















 The results reported in this experimental 
study demonstrate a reduction in the tumor 
incidence for the treated groups. This 
appears to correlate with available clinical 
studies although there has not been a 
prospective randomized study comparing
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thio-tepa to these agents. It should be 
emphasized, however, that most clinical 
trials monitor response by endoscopy. Thus 
thio-tepa eradicates papillary, superficial 
tumors and reduces the recurrence rate 
when used for post-resection prophylaxis. 
These findings might be explained by the 
toxic effect of this drug. Much of the 
exophytic, papillary portion of a tumor 
may be eradicated and the tumor would 
appear to be destroyed endoscopically thus 
preventing a transurethral resection. How-
ever the appearance of tumor cells in the 
urine of patients with no endoscopically 
visible tumors would indicate the lack of 
drug absorption into the basal layers of the 
neoplastic urothelium. Thus with time, 
another visible tumor would develop. This 
of course would be of benefit to the patient 
since it might reduce the frequency of 
endoscopic manipulation and delay, al-
though possibly not prevent, the appearance
of new tumors.
  It is of interest to review the surveillance 
data accumulated by the National Bladder 
Cancer Collaborative Group2). Between 1974 
and October 1977, 1071 patients were 
registered and followed by the Statistical 
Center; 617 had no prior history of bladder 
cancer and the institutional diagnosis was 
confirmed by the central pathology labo-
ratory in 538 of these instances, 259 
patients had invasive cancer or had 
extirpative surgery or radiation therapy 
after entrance into the protocol, 72 patients 
had intravesical chemotherapy. Thus 207 
patients presented for the first time with
transitional cell carcinoma which was 
confined to the mucosa or lamina propria. 
144 of these patients had stage Ta lesions 
and 63 had  T1 tumors. The median 
follow-up was 39 months. Surprisingly only 
two percent of those with grade I tumors 
subsequently developed muscle invasion or 
metastatic disease whereas 11 per cent of 
grade II and 45 per cent of grade III 
tumors subsequently developed muscle in-
vasion. All of those having grade III 
lesions and progressing did so within two 
years of the diagnosis. Only 4 per cent of 
patients haboring a Ta tumor progressed 
compared to 30 per cent with initial T1
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lesions.
  Since all of these patients had selected 
site biopsies at the time of the initial 
endoscopic session, the likelihood of progres-
sion to muscle invasion was compared to 
the findings of these biopsies. There was a 
significantly higher chance of progression 
if moderate or severe dysplasia was found 
in these biopsies compared to normal or 
only mild dysplasia.
 These data clearly underline the hetero-
geneity of superficial bladder cancer and 
emphasize the low likelihood of patients 
with low grade, stage 0 tumors to sub-
sequently develop a deeply invasive bladder
canc r.
Systemic Chemotherapy
  The discovery and subsequent evaluation 
of cis-diamminedichloroplatinum II (DDP) 
not only altered the uniformly rapid demise 
for patients with advanced urothelial 
carcinoma but initiated disease-oriented 
phase II-III trials of single and combination 
chemotherapy in TCC. Prior investigations 
were primarily drug-oriented studies with 
small numbers of patients with bladder 
cancer. The few reports that are available 
lack adequate detail on the extent and 
location of tumor and the criteria for 
response. Patients with evaluable para-
meters such as intra-abdominal or pelvic 
masses were not analyzed separately from 
those with strictly measurable lesions, e.g. 
pulmonary nodules, cutaneous or subcuta-
neous masses, and liver metastases. Since 
e primary tumor may respond differently 
from metastases and since the accuracy of 
evaluation of tumor size depends on location,
this information is critical to the accurate 
assessment of the drug's activity.
 The use of cis-platin in human bladder 
cancer was spurred by a series of experiments
in the FANFT-induced transitional cell 
carcinoma model which identified it as one 
of the most effective drugs inhibiting 
growth of both transplanted and primary 
tumors33-34). The first major clinical evidence 
of its efficacy in human transitional cell 
carcinoma was provided by Yagoda et al.35) 
They observed a 37 per cent objective 
partial response rate; 50 per cent in
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previously untreated patients. The average 
duration of response was five months.
  I have now treated 39 patients with 
locally advanced or metastatic urothelial 
carcinoma with DDP. There were 26 males 
and 13 females. The average age was 66 
(range 41-81) . Twenty-two of the patients
had metastatic disease and 17 had their 
disease confined to the pelvis. The dose 
utilized in all patients was 70 mg/M2 every 
three to four weeks. Only one of these 
patients had prior chemotherapy.
  Mannitol-induced diuresis was uniformly 
instituted to reduce the potential nephro-
toxicity related to DDP. All patients
received a 60 minute infusion of 500 cc of 
5 per cent dextrose in one half normal 
saline followed by 12.5 mg mannitol by 
intravenous push prior to receiving DDP.
The DDP was infused over 15 minutes. 
Following the DDP an additional 500 cc 
of 5% dextrose in one half normal saline 
was infused during the next 60-90 minutes.
 All patients received a minimum of two 
doses of DDP. Responses were usually 
evident within six weeks. A complete 
response was defined as complete disappear-
ance of all tumor. A partial response 
required a 50 per cent or more reduction 
in the sum or the products of two perpen-
dicular diameters of the tumor and no new 
lesions or increase in the size of any existing
lesions. Patients with tumor confined to the 
bladder or pelvis were evaluated by 
cystoscopy (if the bladder was present), 
bimanual examination under anesthesia, 
and usually a CAT scan.
 None of the patients achieved a complete 
response (Table 7). Eleven (28 per cent) 
achieved a partial response while an 
additional 16 (41 per cent) remained stable
for a minimum of two months. The
Table 7. CIS-platin in advanced urothelial 


















average duration of response for both the 
partial responders and those remaining
stable was six months.
  Twenty-two patients had bidimensionally 
measurable metastatic disease. Seven (32 
per cent) achieved a partial response and 
an equal number remained stable. The 
response rates for the 17 patients whose
dis ase was confined to the bladder or 
pelvis at the time of initiation of chemo-
th rapy were also analyzed separately. 
Four (23 per cent) achieved a partial 
response while nine (54 per cent) were 
stabilized. The average response duration 
was five and eight months respectively.
 Utilizing the life table method, the 
probability of surviving six months for 
patients receiving a partial response, 
remaining stable, or progressing was 78 per 
cent, 84 per cent, and 17 per cent respective-
ly. Thus stabilization of the disease appeared 
to be as efficacious in regard to survival as 
those achieving an objective regression. In 
addition, the probability of surviving six or 
twelve months for patients with metastatic 
disease was approximately 50 per cent 
compared to 85 per cent for those whose 
tumor was confined to the bladder or pelvis. 
At twelve months these figures were 29 and 
61 per cent respectively.
Efforts to further improve upon the 
results achieved by DDP alone have 
prompted trials employing combination 
chemotherapy. In general the results from 
our murine studies indicate a slightly 
greater reduction in tumor with the addition 
of cytoxan and/or adriamycin to DDP when 
compared to cis-platin used alone. Clinical 
reports indicate a 2-3 month longer 
response duration with a two or three drug 
regimen; however, the response rates are 
approximately the same as achieved with 
DDP alone. Toxicity is increased when 
these myelosuppressive drugs are added to 
DDP. Yagoda36> found the combination of 
cytoxan -±DDP to yield an identical response 
rate to that achieved by DDP alone. 
Similar results were observed by these 
investigators with a combination of DDP 
and adriamycin. Samuels et al.37) observed 
an objective response rate of 41 per cent 
(17/41) when combining cytoxan, adria-
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mycin and high dose cis-platin. It should 
be indicated, however, that among these 
responses were seven complete responses.
 Although nephrotoxicity resulting from 
DDP is a potentially serious complication, 
the routine use of hydration and mannitol-
induced diuresis has largely obviated this 
problem. Almost all of the patients who 
had a serum creatinine rise significantly 
under therapy with DDP had either a 
solitary kidney or significant ureteral
obstruction.
 The National Bladder Cancer Collaborat-
ive Group recently completed a prospective 
randomized protocol to compare the efficacy 
of cis-platin, 70 mg/M2 IV every three 
weeks to  cis-platin  +cyclophosphamide, 750 
mg/M2 given in the same intervals38). 
Response was assessed at the nine week 
interval following three courses of chemo-
therapy. Patients were stratified into four 
groups depending on whether they had
measurable or evaluable disease as well as 
upon their performance status. Measurable 
disease was classified as pulmonary nodules, 
enlarged lymph nodes or cutaneous masses 
which were measurable in two dimensions. 
None of the patients received prior systemic 
chemotherapy and at least four weeks must 
have elapsed since prior radiation therapy. 
Hematologic status and renal function were 
required to be normal. 127 patients were 
accessioned into the protocol and 105 were 
evaluable for response.
  Ten of 49 patients (20.4 per cent) receiv-
ing cis-platin alone had an objective 
response compared to only seven of 56 
patients (12.5 per cent) who received the 
combination. There was no statistically 
significant difference between these response 
rates. There were complete responses evident 
in both treatment categories, four receiving 
the single agent and two the combination. 
Approximately one third of the patients in 
each group were stabilized as a result of 
this chemotherapeutic regimen. The median 
time to response was 73 days.
  Evaluation of response as a function of 
performance status indicated that patients 
with a better performance status receiving 
DDP alone had a 23.3 per cent complete or 
partial response rate compared to 15.8 per
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cent of those in the lower performance 
tatus category. The respective response 
rates for patients receiving the combination 
were 15.2 per cent and 8.7 per cent respec-
tively. There was no significant difference 
between the response rates for those having 
either measurable or evaluable disease.
 Evaluation of survival indicated no differ-
ence between the two treatment regimens. 
There was a far greater likelihood of 
surviving six months for patients having 
either an objective response or remaining 
stable with no apparent difference in 
survival between these response categories.
  It is evident from the above review of our 
results with cis-platin and those of other 
single investigator or cooperative groups 
that there is a need to greatly improve 
chemotherapy for patients with advanced 
urothelial carcinoma. As part of our con-
tinuing studies to screen prospective anti-
tumor drugs for activity in the FANFT-
induced transitional cell carcinoma in 
murine model, we have recently evaluated 
VP16-213.
 Etoposide or VP16-213 is a semi-synthetic 
derivative of podophyllotoxin. Its mode of 
action consists of metaphase arrest and 
premitosis inhibition. Several phase II 
trials have indicated that among the disease 
categories for treatment with VP16 showing 
promise is urinary bladder cancer. The 
number of patients, however, with bladder 
cancer receiving this agent were few. 
These reports also lack sufficient detail on 
the extent of tumor and the criteria for 
response to be meaningful. The maximum 
tolerated dose of VP16 was determined to 
be between 40 and 50 mg/kg.
 In an initial series of studies the trans-
plantable murine bladder cancer, MBT2, 
was utilized. A single cell suspension of the 
tumor was prepared and 7.5 x 104 viable 
cells were placed 1M in the left hind limb 
of 64 C3H/He mice. The animals were 
randomly divided into a control and four 
treatment groups. Therapy was initiated 
n day seven and continued weekly for 
three doses. The therapeutic regimens 
consisted of: VP16, 50, 55 or 60 mg/kg or 
DDP, 6 mg/kg. Drugs were given by the 
intraperitoneal route.
 Soloway  : Treatment
 A second study involved 44 C3H/He mice 
divided into a control group of 20 and two 
treatment groups of 12 mice each. The 
doses of VP16 and DDP were 50 and 6 
mg/kg respectively.
  All mice were examined daily to deter-
mine the onset of palpable tumors. Tumor 
growth was determined by biweekly 
measurement of tumor diameter and an 
average computed. The increase in life 
span (ILS) of treated mice was compared 
to that of the untreated tumor-bearing 
control group. The percent ILS was 
calculated by subtracting the median 
survival time (MST) of the control group 
from the treated group divided by the MST 
of the control x 100. The ILS takes into 
account deleterious effects resulting from 
drug toxicity.
  Tumor incidence was 100 per cent in all 
of the groups. DDP and each of the three 
doses of VP16 produced a significant re-
duction in the mean tumor diameter as 
measured on day 23. Although the higher 
doses of VP16 yielded somewhat greater 
inhibition, the ILS was highest in the mice 
receiving a dose of 50 mg/kg. The ILS 
of mice receiving this dose of VP16 was 
superior to the group receiving DDP. In 
the second study, once again VP16 and 
DDP demonstrated significant reduction in 
mean tumor diameter compared to the 
control group. The ILS of those receiving 
DDP was superior to mice being treated
with VP16.
 The effect of VP16 and DDP was also 
evaluated in a long-term study in 111 
female C3H/He mice fed a diet containing 
0.1 per cent FANFT for 39 weeks. Once 
again the animals were randomly divided 
into a control group (31) and four treatment 
groups of 20. Therapy consisted of VP16, 
50 mg/kg; DDP, 6 mg/kg; VP16, 40 mg/kg 
+DDP, 4 mg/kg; or VP16, 50 mg/kg +DD 
P, 6 mg/kg. Drugs were given IP in a 
volume of 0.1 cc for four weeks. All of the 
bladders of the surviving mice were excised 
at week 46. The bladders were weighed 
and step histologic sections obtained to 
determine tumor incidence and stage.
 The mice receiving the lower dose of the 
DDP-VP16 combination had a significant
of bladder cancer1549
reduction in the incidence of tumors 
compared to the controls (50 per cent vs 
96 per cent). The primary difference was 
the lack of carcinoma in situ in the treatment 
group. The only group having a significant 
reduction in the mean log bladder weight 
we e those receiving the combination of 
DDP+VP16, 50 mg/kg.
  In this long-term study utilizing primary 
FANFT-induced bladder tumors, mice 
ceiving DDP had a reduction of tumor 
incidence compared to the control group 
while those receiving VP16 did not have 
such a reduction. Mice receiving the low 
dose DDP-VP16 combination had a signifi-
cant reduction in tumor incidence while 
the higher dose combination had a signifi-
cant reduction in the mean bladder weight. 
Thus the antineoplastic activity of this 
combination was more effective than either 
of the drugs utilized alone. 
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近 年,表 在 性 膀 胱 腫 瘍 の 手 術 後 の高 い再 発 頻 度 が 問
題 と な って い る が,こ の 再発 の 病 因 はnewoccurren-
cesとtruerecurrencesの2つに 大 別 さ れ,前 者 は腫
瘍 の 多中 心 発 生 に,後 者 は 手 術 時 の腫 瘍 細 胞 の膀 胱 内
播 種 に よ る と考 」えら れ,と くにtruerecurrencesに
ついては動物実験によって腫瘍細胞が電灼部位に播種
することを証明した-






を中心 とす る多剤併用療法は現時点では余 り有効 とは
いえない.し か し動物実験ではCDDPとVP16の
併用が良い成績を示している,
